Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 134 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2016', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
- The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects
- The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Non Alcoholic Fatty Liver Disease (NAFLD) Overview 10
Therapeutics Development 11
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 11
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis 12
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies 13
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes 15
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies 19
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes 21
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 22
Arisaph Pharmaceuticals, Inc. 22
AstraZeneca Plc 23
Betagenon AB 24
Can-Fite BioPharma Ltd. 25
Conatus Pharmaceuticals Inc. 26
Corcept Therapeutics Incorporated 27
Daewoong Pharmaceutical Co., Ltd. 28
Dimerix Bioscience Pty Ltd 29
Dr. Falk Pharma GmbH 30
DURECT Corporation 31
Galmed Pharmaceuticals Ltd. 32
Gilead Sciences, Inc. 33
Huons Co., Ltd. 34
Kyorin Pharmaceutical Co., Ltd. 35
Novartis AG 36
Sancilio & Company, Inc. 37
TaiwanJ Pharmaceuticals Co., Ltd. 38
TCM Biotech International Corp 39
Tobira Therapeutics, Inc. 40
Verva Pharmaceuticals Limited 41
Zafgen Inc. 42
Zydus Cadila Healthcare Limited 43
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 54
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(leucine + PDE5 Inhibitor) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Aramchol - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ARI-3037MO - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
C-10 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
cenicriviroc mesylate - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CF-102 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CORT-118335 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
DMX-300 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DUR-928 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
DWP-10292 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
emricasan - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
FLB-12 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GS-9674 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
HU-002 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
KDT-501 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MAT-8800 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
methazolamide - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
MN-002 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
naltrexone hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
norursodeoxycholic acid - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
O-304 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
oltipraz - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
pradigastat sodium - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Px-103 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
saroglitazar - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
SC-410 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
TCM-606F - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
VVP-100-X - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ZGN-839 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Non Alcoholic Fatty Liver Disease (NAFLD) - Recent Pipeline Updates 102
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 122
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 123
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 124
Featured News & Press Releases 124
Jan 11, 2016: Can-Fite Announces Update on CF102 124
Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 124
Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment 125
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 126
Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease 126
May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study 127
Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 128
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 129
Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 130
Mar 26, 2015: Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan 131
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 133
Disclaimer 134

List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2016 11
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Development by Companies, H1 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 22
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2016 23
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2016 24
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd., H1 2016 25
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 26
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Incorporated, H1 2016 27
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 28
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2016 29
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2016 30
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corporation, H1 2016 31
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd., H1 2016 32
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences, Inc., H1 2016 33
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co., Ltd., H1 2016 34
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 35
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H1 2016 36
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company, Inc., H1 2016 37
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 38
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H1 2016 39
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Tobira Therapeutics, Inc., H1 2016 40
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Verva Pharmaceuticals Limited, H1 2016 41
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zafgen Inc., H1 2016 42
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 43
Assessment by Monotherapy Products, H1 2016 44
Assessment by Combination Products, H1 2016 45
Number of Products by Stage and Target, H1 2016 47
Number of Products by Stage and Mechanism of Action, H1 2016 50
Number of Products by Stage and Route of Administration, H1 2016 52
Number of Products by Stage and Molecule Type, H1 2016 53
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Recent Pipeline Updates, H1 2016 102
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H1 2016 122
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H1 2016 123